S.Africa probes 3 drug giants over cancer meds pricing

June 13, 2017

South Africa's competition commission said Tuesday it had launched investigations into pharmaceutical giants Roche, Pfizer and Aspen for suspected overpricing of cancer drugs.

Swiss firm Roche and US company Pfizer are being probed over "excessive pricing" for breast and lung cancer medications respectively, while South Africa's Aspen is being investigated for overcharging over three different drugs.

"The commission has reason to believe that Roche and its USA-based biotechnology company, Genentech, have and continue to engage in excessive pricing, price discrimination... in the provision of breast cancer medicine in South Africa," it said in a statement.

It said it suspected Roche of engaging in anti-competitive conduct, prolonging its "hold on breast cancer drugs" and preventing cheaper generic alternatives from reaching the market.

Roche is also accused of charging different rates to private and public sector patients, possibly in breach of local competition laws.

The Swiss giant said it had not yet been notified of the investigation.

If notified, "we will be cooperating with the authorities and will provide all required information while responding to the potential allegation," said Roche.

The South African commission said it had "also initiated an investigation against pharmaceutical giant, Pfizer, for suspected excessive pricing of lung cancer medication in South Africa".

The commission is also investigating South Africa's Aspen for overcharging for three drugs used in the treatment of various strains of cancer including leukaemia, myeloma and ovarian cancer.

It suspects Aspen of "abuse of dominance by charging excessive prices in the provision of lifesaving cancer medicines in South Africa".

Aspen denied the allegations saying that pharmaceutical prices in the country are approved by the health ministry which establishes a universal fixed price for each drug.

"Aspen has not increased pricing of its products outside of this regulatory framework and has clearly demonstrated its commitment to providing quality medicines affordably over many years," it said in a statement.

"The supply of the oncology products in question is no exception."

Aspen is already under investigation in the European Union over suspicions that it abused its dominant market position in breach of EU antitrust rules.

The EU probe was announced last month.

Explore further: Roche buying Seragon in US for up to $1.7 billion

Related Stories

Roche buying Seragon in US for up to $1.7 billion

July 2, 2014
Roche Holding AG says its U.S.-based biotech company Genentech has agreed to acquire American biotechnology firm Seragon Pharmaceuticals, Inc. for up to $1.725 billion in cash and contingency payments.

Roche probed for not reporting side effects

October 23, 2012
(AP)—Europe's top drug regulator announced Tuesday it is taking action against pharmaceutical giant Roche for allegedly failing to properly report the side effects of 19 drugs being used by U.S. patients.

EU regulator: No more problems with Roche drugs

November 19, 2013
The European Medicines Agency says it has finished an investigation of the way pharmaceutical giant Roche reported side effects for 19 drugs in the U.S. and has found no new safety concerns.

FDA approves Roche's Avastin for ovarian cancer

November 14, 2014
Swiss drugmaker Roche said Friday that the Food and Drug Administration approved its drug Avastin as a treatment for ovarian cancer.

Roche breast cancer drug 'helps patients live longer': study

September 29, 2014
A drug developed by Swiss giant Roche to treat an aggressive form of breast cancer has been shown to extend patients' lives by almost 16 months, researchers said Sunday.

Roche warns of counterfeit cancer drug in US

February 14, 2012
(AP) -- The maker of the best-selling cancer drug Avastin is warning doctors and patients about counterfeit vials of the product distributed in the U.S.

Recommended for you

In most surgery patients, length of opioid prescription, number of refills spell highest risk for misuse

January 17, 2018
The possible link between physicians' opioid prescription patterns and subsequent abuse has occupied the attention of a nation in the throes of an opioid crisis looking for ways to stem what experts have dubbed an epidemic. ...

Patients receive most opioids at the doctor's office, not the ER

January 16, 2018
Around the country, state legislatures and hospitals have tightened emergency room prescribing guidelines for opioids to curb the addiction epidemic, but a new USC study shows that approach diverts attention from the main ...

FDA bans use of opioid-containing cough meds by kids

January 12, 2018
(HealthDay)—Trying to put a dent in the ongoing opioid addiction crisis, the U.S. Food and Drug Administration on Thursday slapped strict new restrictions on the use of opioid-containing cold and cough products by kids.

Taking ibuprofen for long periods found to alter human testicular physiology

January 9, 2018
A team of researchers from Denmark and France has found that taking regular doses of the pain reliever ibuprofen over a long period of time can lead to a disorder in men called compensated hypogonadism. In their paper published ...

Nearly one-third of Canadians have used opioids: study

January 9, 2018
Nearly one in three Canadians (29 percent) have used "some form of opioids" in the past five years, according to data released Tuesday as widespread fentanyl overdoses continue to kill.

Growing opioid epidemic forcing more children into foster care

January 8, 2018
The opioid epidemic has become so severe it's considered a national public health emergency. Addiction to prescription painkillers, such as oxycodone and morphine, has contributed to a dramatic rise in overdose deaths and ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.